Spermidine in hypertension: therapeutic potential and novel mechanisms

Project description

Spermidine: a new medication against hypertension?

Hypertension is a leading cause of cardiovascular disease, with only one third of patients achieving efficient blood pressure control with existing medications. Accumulating evidence indicates that spermidine, an endogenous activator of autophagy and dietary supplement, correlates with lower blood pressure in humans. The EU-funded SPeR-ToNE project will capitalise on this observation to provide insight into the mechanism by which spermidine counteracts hypertension. Researchers will apply a multitude of cutting-edge techniques, animal models and human samples to study the cross-talk between blood pressure control and autophagy. Results will pave the way towards the development of novel interventions against hypertension.

Fields of science

• social sciences › sociology › demography › mortality
• natural sciences › biological sciences › cell biology
• medical and health sciences › clinical medicine › cardiology › cardiovascular diseases

Programme(s)

• H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme
• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Topic(s)

• MSCA-IF-2020 - Individual Fellowships

Call for proposal

H2020-MSCA-IF-2020

See other projects for this call

Funding Scheme

MSCA-IF-EF-ST - Standard EF

Coordinator

INSTITUT GUSTAVE ROUSSY

Net EU contribution

€ 196 707,84

Address

Rue Camille Desmoulins 39
94805 Villejuif
France

Region

Ile-de-France › Ile-de-France › Val-de-Marne

Activity type

Research Organisations

Links

Other funding

€ 196 707,84